Denali Therapeutics
DNLI
250 hedge funds and large institutions have $2.5B invested in Denali Therapeutics in 2025 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 86 increasing their positions, 71 reducing their positions, and 34 closing their positions.
298% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $537K
50% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 34
27% more capital invested
Capital invested by funds: $1.97B → $2.5B (+$528M)
21% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 71
10.38% more ownership
Funds ownership: 92.67% → 103.06% (+10%)
4% more funds holding
Funds holding: 240 → 250 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$28.2M |
| 2 |
Temasek Holdings
Singapore
|
+$28M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$27.3M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$24.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$22.2M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$17.4M |
| 3 |
Millennium Management
New York
|
-$15.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11M |
DNLI Hedge Fund Activity: Q4 2025 in Review
250 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2025, worth a combined $2.5B — up 27% from $1.97B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new DNLI positions and 34 closed out — a net gain of 17 holders — while 86 added to existing stakes and 71 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $28.2M. The largest seller was Stempoint Capital, cutting an estimated $22.2M.
- 250 institutional investors held Denali Therapeutics (DNLI) as of Q4 2025, up from 240 in Q3 2025.
- Funds reported $2.5B of Denali Therapeutics stock for Q4 2025, up 27% quarter-over-quarter.
- 51 funds opened new Denali Therapeutics positions in Q4 2025 and 34 closed out, a net change of +17 holders.
- The largest Denali Therapeutics buyer in Q4 2025 was Goldman Sachs, an estimated $28.2M added.
- The largest Denali Therapeutics seller in Q4 2025 was Stempoint Capital, an estimated $22.2M sold.
Based on aggregated 13F filings for Q4 2025.